DEPARTMENT OF HEALTH SERVICES

Division of Medicaid Services F-02667 (07/2020)

STATE OF WISCONSIN

Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEADACHE AGENTS, PREVENTATIVE TREATMENT

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Headache Agents, Preventative Treatment Instructions, F-02667A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Headache Agents, Preventative Treatment form signed by the prescriber before submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION							
Name – Member (Last, First, Middle Initial)							
2. Member ID Number	3. Date of Birth – Member						
SECTION II – PRESCRIPTION INFORMATION							
4. Drug Name	5. Drug Strength						
6. Date Prescription Written	7. Refills						
8. Directions for Use							
9. Name – Prescriber	10. National Provider Identifier – Prescriber						
11. Address – Prescriber (Street, City, State, Zip+4 Code)							
12. Phone Number – Prescriber							
SECTION III - CLINICAL INFORMATION - ALL REQUES	TS						

13. Diagnosis Code and Description

Note: A copy of the member's medical records must be submitted with all PA requests for headache agents, preventative treatment drugs. Medical records must document the member's medical work-up for migraines, including complete problem and medication lists.



SECTION IV - CLINICAL INFORMATION - INITIAL REQUESTS ONLY				_
14. Is the member 18 years of age or older?		Yes		No
15. Has the prescriber evaluated and diagnosed the member as having a history of migraine, with or without aura, according to the International Classification of Headache Disorders, 3 rd edition, diagnostic criteria?		Yes		No
16. Document the member's current migraine prescribed medication treatment regimen.				
List the current prescribed migraine preventative medications (drug name[s], dose, and dos including Botox (if applicable).	ing fre	equenc	у),	
List the current prescribed migraine rescue medications (drug name[s], dose, and dosing fro	equer	ncy).		
	-			
17. Has the member taken Ajovy for at least three consecutive months and experienced		V		NI.
an unsatisfactory therapeutic response or a clinically significant adverse drug reaction?		Yes		No
If yes, indicate the dose, the approximate dates taken, and specific details about the unsati	sfacto	ry thera	peuti	ic
response or clinically significant adverse drug reaction.				
18. Has the member taken Emgality 120 mg for at least three consecutive months and				
experienced an unsatisfactory therapeutic response or a clinically significant adverse				
drug reaction?		Yes		No
If yes, indicate the dose, the approximate dates taken, and specific details about the unsatiresponse or clinically significant adverse drug reaction.	sfacto	ry thera	ıpeuti	c

-02	007 (07/2020)					
SE	CTION V – CLINICAL INFORMATION – RENEWAL REQUESTS ON	LY				
19.	Has the member experienced/sustained a clinically significant decrea migraine days per month and/or a decrease in migraine duration com prior to initiation of treatment with a headache agent, preventative treatment	pared to their baseline		Yes		No
20.	20. List the current prescribed migraine preventative medications (drug name[s], dose, and dosin including Botox (if applicable).					
	List the current prescribed migraine rescue medications (drug name[s	s], dose, and dosing free	quen	ncy).		
	Has the member been compliant with the current prescribed migraine medication treatment regimen?				٥	No
SE	CTION VI – AUTHORIZED SIGNATURE					
21.	SIGNATURE – Prescriber	22. Date Signed				
SE	CTION VII – ADDITIONAL INFORMATION					
23.	Include any additional information in the space below. Additional diagneed for the drug requested may be included here.	nostic and clinical inforr	natio	on expla	ining	; the